Studie om GcMAF publisert i oktober 2010
Følgende studie ble publisert oktober 2010 ifb med prostata kreft. Jeg syntes det er aktuelt å publisere dette her på bloggen nå da det er mange av oss som er i gang med GcMAF behandling for det HIV-liknende retroviruset XMRV.
Hentet fra PlosOne:
Vitamin D binding protein-macrophage activating factor (DBP-maf) is a potent inhibitor of tumor growth. Its activity, however, has been attributed to indirect mechanisms such as boosting the immune response by activating macrophages and inhibiting the blood vessel growth necessary for the growth of tumors.
Methods and Findings
In this study we show for the first time that DBP-maf exhibits a direct and potent effect on prostate tumor cells in the absence of macrophages. DBP-maf demonstrated inhibitory activity in proliferation studies of both LNCaP and PC3 prostate cancer cell lines as well as metastatic clones of these cells. Flow cytometry studies with annexin V and propidium iodide showed that this inhibitory activity is not due to apoptosis or cell death. DBP-maf also had the ability to inhibit migration of prostate cancer cells in vitro. Finally, DBP-maf was shown to cause a reduction in urokinase plasminogen activator receptor (uPAR) expression in prostate tumor cells. There is evidence that activation of this receptor correlates with tumor metastasis.
These studies show strong inhibitory activity of DBP-maf on prostate tumor cells independent of its macrophage activation.»
Les det HER
Les det på norsk med Google Translater HER